La medicacin que se utiliza aqu para obesidad es liraglutida, que tambin es un agonista de GLP-1 pero es de aplicacin diaria, a diferencia de semaglutida, que es de aplicacin semanal
This will show us if doctors will use retatrutide more for obesity treatments in the future
This is the critical transition period
New medications like GLP-1s are reshaping how many people approach weight loss and we are embracing this next chapter of innovation
Recent multi-omics analyses by Cappellani et al., for instance, have provided strong genetic and proteomic evidence linking DR pathogenesis directly to the activation of specific immune pathways, including the complement system and adaptive T-cell responses [53, 58, 59]
In the future, with the in-depth exploration of the mechanism of GLP-1R action and the development of multi-target agonists (e.g., GLP-1R/GIPR dual agonists), GLP-1R-related therapeutics are expected to make breakthroughs in a wider range of disease areas (e.g., nonalcoholic steatohepatitis, AD, etc.), providing a more precise and highly effective strategy for the treatment of metabolic diseases and related complications
![Painter's Servant (Borderless) [SPG - 147] Language:English](https://cdn.shopify.com/s/files/1/0450/0021/files/671008.jpg?v=1769102431)
